Drugs / GLB-001
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06378437 | May 2024 → Dec 2026 expected | acquired polycythemia vera, acute myeloid leukemia, essential thrombocythemia, myelodysplastic syndrome +1 | Hangzhou GluBio Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT06146257 | Jan 2024 → Jul 2026 overdue | acute myeloid leukemia, myelodysplastic syndrome | GluBio Therapeutics Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GLB-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06378437 ↗ |
| Route | Oral | “Administered orally according to the assigned treatment schedule” NCT06146257 ↗ |